A Proof-of-Concept Study for the Efficacy of Dispirotripiperazine PDSTP in a Mouse Model of Herpes Simplex Herpetic Encephalitis
Viruses · 2026
DOI: 10.3390/v18090944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Kristina Pomeshikova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Federal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences (Research Centre of Biotechnology RAS), 33-2 Leninsky Pros…. Hauptthemen laut MEDLINE: Encephalitis, Herpes Simplex, Antiviral Agents, Piperazines, Herpesvirus 1, Human. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Herpes simplex encephalitis (HSE) remains a life-threatening disease with high mortality and severe neurological complications, despite acyclovir therapy being limited by delayed diagnosis, drug resistance, and poor blood–brain barrier penetration. New antivirals with different mechanisms of action are urgently needed. We evaluated PDSTP, a novel dispirotripiperazine-based compound targeting host heparan sulfate proteoglycans (HSPGs), in mouse models of HSV-1 encephalitis. This study evaluates the therapeutic and prophylactic potential of PDSTP, an antiviral compound that blocks HSV glycoconjugates on the host cell membrane, using a well-established mouse model of herpes encephalitis. BALB/c mice were infected with HSV-1 strains VR-539 or VR-733 via intraperitoneal (IP) or intranasal (IN) routes. PDSTP was administered orally (PO) or intraperitoneally (IP) at 12.5–80 mg/kg/day, alone or in combination with acyclovir (10–100 mg/kg/day), using a prophylactic–therapeutic regimen (2 h pre-infection, then twice daily for 7 days). Survival, weight loss, mean survival time, and brain viral loads were assessed. PDSTP at 80 mg/kg/day (PO) protected 30–40% of VR-733-infected mice and extended lifespan 1.9-fold (p < 0.05), comparable to acyclovir at 100 mg/kg/day. IP administration was superior to PO. The combination of IP PDSTP (12.5 mg/kg/day) with IP acyclovir (10 mg/kg/day) achieved 100% survival, prevented weight loss, and significantly reduced brain viral titers (p < 0.001) in both infection models. PDSTP demonstrates dose- and strain-dependent activity as monotherapy and enhanced efficacy when combined with acyclovir. The IP combination provided complete protection at low doses, supporting PDSTP as a promising candidate for further development against HSE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences (Research Centre of Biotechnology RAS), 33-2 Leninsky Prospect, Moscow 119071, Russia.
- I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
- Department of Virology, Mechnikov Research Institute of Vaccines and Sera, Moscow 105064, Russia.
- Microbiology and Virology Unit, Department of Biomedical Science, University of Cagliari, 09042 Monserrato, Italy.
ORCID-Profile: Giuseppina Sanna, Vadim Makarov
Förderung
- Russian Science Foundation
Zitieren
APA
Pomeshikova, K., Riabova, O., Monakhova, N., Leneva, I., Sanna, G., & Makarov, V. (2026). A Proof-of-Concept Study for the Efficacy of Dispirotripiperazine PDSTP in a Mouse Model of Herpes Simplex Herpetic Encephalitis. Viruses. https://doi.org/10.3390/v18090944
Vancouver
Pomeshikova K, Riabova O, Monakhova N, Leneva I, Sanna G, Makarov V. A Proof-of-Concept Study for the Efficacy of Dispirotripiperazine PDSTP in a Mouse Model of Herpes Simplex Herpetic Encephalitis. Viruses. 2026. doi:10.3390/v18090944
BibTeX
@article{Pomeshikova2026,
author = {Pomeshikova, Kristina and Riabova, Olga and Monakhova, Natalia and Leneva, Irina and Sanna, Giuseppina and Makarov, Vadim},
title = {A Proof-of-Concept Study for the Efficacy of Dispirotripiperazine PDSTP in a Mouse Model of Herpes Simplex Herpetic Encephalitis},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18090944}
}
EUVIMED